Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery - Summary - MDSpire

Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2alpha inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

  • By

  • June 12, 2026

  • 3 min

Share

Objective:

To report the FDA approval of pembrolizumab and belzutifan as adjuvant treatment for higher-risk clear cell renal cell carcinoma (ccRCC) post-surgery.

Approach:
  • Study Design: The phase 3 LITESPARK-022 trial involved 1,841 participants with ccRCC who underwent surgery and were at high risk of recurrence.
  • Treatment Comparison: Patients were randomized to receive either pembrolizumab plus belzutifan or pembrolizumab plus placebo after surgery.
Key Findings:
  • The combination therapy resulted in a 28% decrease in the risk of recurrence, metastasis, or death based on the trial results.
  • Approximately 81% of participants on the combination therapy were cancer-free after 24 months, compared to 74% on the placebo.
Interpretation:

This approval establishes pembrolizumab and belzutifan as a new adjuvant option for patients with ccRCC at increased risk of recurrence.

Limitations:
  • The study's follow-up period was a median of 28.4 months.
  • Side effects were consistent with data from previously reported studies.
Conclusion:

This is the first approval for belzutifan in earlier-stage ccRCC and the first for a PD-1 and HIF-2alpha inhibitor combination regimen.

Sources:

Original Source(s)

Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery

  • by

  • June 12, 2026

Related Content

Trends in liver failure-related mortality among middle-aged and older adults with digestive system malignant tumors in the United States, 1999–2023

Precision medicine directed therapy enabling long-term survival in medulloblastoma: a case report

Leptomeningeal disease (LMD) after resection of brain metastases: results of the multicenter SUBAROMA study